The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) guidelines have recently been updated to account for the EAU RCC guidelines panel’s recommendation about adjuvant therapy with sunitinib for people with non-metastatic RCC after surgical removal of the tumour. These clinical guidelines provide urologists with evidence-based information and recommendations for the management of RCC and the panel includes urological surgeons, oncologists, pathologists, radiologists and patient advocates. Based on the conflicting results of two clinical studies (ASSURE and S-TRAC), the panel, including representatives from the International Kidney Cancer Coalition representing patient advocate groups globally, recommended that adjuvant therapy with sunitinib for patients with high-risk RCC after nephrectomy should not be given.

Read the updated EAU RCC guidelines here

Read more here